Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 7, 2004. The report addresses a significant development in a long-running tax dispute with the US Internal Revenue Service (IRS) regarding legacy company Glaxo Wellcome.
Key Financial Metrics
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The only financial figures disclosed relate to the specific tax dispute:
- Statutory Notice of Deficiency: $2.7 billion (£1.5 billion) in additional taxes claimed for the years 1989 to 1996.
- Estimated Interest: Approximately $2.5 billion (£1.4 billion) net of federal tax relief, if the full claim is upheld.
- Open Periods: Similar tax issues remain unresolved for the years 1997 to 2000, with an additional assessment expected.
Material Changes and Contingencies
The primary material change is the receipt of a formal "statutory notice of deficiency" from the IRS. The dispute concerns the allocation of taxes on profits for Glaxo heritage products between the US and other countries. GSK notes that negotiations between US and UK tax authorities collapsed after the UK supported GSK's position that no additional taxes were due. The company believes the IRS claim is inconsistent with the treatment of other pharmaceutical companies, including GSK's legacy company SmithKline Beecham.
Management Commentary and Outlook
Management states that, based on external professional advice, GSK has made adequate provision for tax liabilities that could arise from these assessments. The company plans to contest the claim by filing a petition in the US Tax Court, with a trial not expected until 2005-2006. GSK maintains that the profits reported by its US subsidiaries for 1989-2000, on which taxes were already paid, are sufficient to reflect US operations. The filing includes a standard cautionary statement regarding forward-looking statements and references risk factors detailed in the 2002 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the adequacy of existing tax provisions in GSK's financial statements against the $2.7 billion claim plus estimated interest.
- Monitor the timeline for the US Tax Court petition and the expected trial date (2005-2006).
- Assess the potential impact of additional assessments for the 1997-2000 period, which GSK anticipates receiving.
- Review the 2002 Annual Report on Form 20-F for detailed risk factors related to global tax operations.